One study, for the safety and efficacy of APR-246 in combination with azacitidine and to assess complete remission (CR) of the patients with TP53-mutated myeloid neoplasm alone and in combination with azacitidine (AZA, vidaza) (NCT03588078) [95] (Table 1), and one to determine the safety and recommended dose of APR-246 in combination with azacitidine as well as to see if this combination of therapy improves overall survival (OS) (NCT03072043) [96]. The gene discussed is TP53; the disease is myeloid neoplasm.